A Phase I Trial of IGF-IR Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-Resistant Prostate Cancer

In metastatic CRPC, poor single agent response to Torc1 inhibition is postulated in part due to release of negative feedback on the PI3k/Akt/mTOR pathway. This phase I study of 16 patients aimed to overcome resistance to Torc1 inhibition monotherapy with concurrent IGF-1R inhibition. Results showed...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2020-01, Vol.18 (3), p.171-178.e2
Main Authors: McHugh, Deaglan J., Chudow, Jay, DeNunzio, Mia, Slovin, Susan F., Danila, Daniel C., Morris, Michael J., Scher, Howard I., Rathkopf, Dana E.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In metastatic CRPC, poor single agent response to Torc1 inhibition is postulated in part due to release of negative feedback on the PI3k/Akt/mTOR pathway. This phase I study of 16 patients aimed to overcome resistance to Torc1 inhibition monotherapy with concurrent IGF-1R inhibition. Results showed limited antitumor activity and higher than anticipated toxicity. The trial was stopped in favor of alternative AR/PI3K-directed combinatorial therapies.
ISSN:1558-7673
1938-0682
DOI:10.1016/j.clgc.2019.10.013